ReviewJournal of lipid and atherosclerosis2024
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.
Review in Journal of lipid and atherosclerosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2024Pooled it
- Review
- A Case of Familial Chylomicronemia Syndrome Caused by a Novel Homozygous GPIHBP1 Mutation Successfully Treated with the Selective PPARα Modulator Pemafibrate.Journal of atherosclerosis and thrombosis · 2026Article
- Strenuous Exercise and Quercetin Supplementation Differentially Alter Lipid Metabolism in C57BL/6J Mice.Journal of lipid and atherosclerosis · 2026Article
- Article
- Hypertriglyceridaemia and its multifaceted mechanisms driving atherosclerotic cardiovascular disease.Lipids in health and disease · 2026Review
- Treatment Target Discovery From Vasculo-Protective Phenotypes.Journal of lipid and atherosclerosis · 2026Review
- Acute pancreatitis caused by severe hypertriglyceridemia in a 61-year-old man on a carnivore diet.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Current and Emerging Pharmacological Therapies for Hypertriglyceridemia.International journal of molecular sciences · 2026Review
- Clinical Determinants and Prognostic Significance of Circulating Angiopoietin-Like Protein 3 Levels in Patients With Chronic Coronary Syndrome.Circulation reports · 2026Article
- Review
- Olezarsen and Beyond: Emerging Targeted Treatments for Familial Chylomicronemia Syndrome and Related Triglyceride Disorders.Journal of lipid and atherosclerosis · 2026Review
- Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Managing dyslipidemia in chronic kidney disease: a comprehensive overview of evidence and recommendations.The Korean journal of internal medicine · 2025Review
- Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- The impact of olezarsen on hypertriglyceridemia in high cardiovascular risk patients: a systematic review, meta-analysis, and meta-regression.Annals of medicine and surgery (2012) · 2025Article
- Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study.Circulation. Genomic and precision medicine · 2025Review
- Single-cell transcriptome-wide Mendelian randomization and colocalization analyses uncover cell-specific mechanisms in atherosclerotic cardiovascular disease.American journal of human genetics · 2025Article
- GHRH in diabetes and metabolism.Reviews in endocrine & metabolic disorders · 2025Review
- Phytyl Phenolipids: Structurally Modified Antioxidants with Superior Lipid Membrane Interaction.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apolipoprotein C3 (apoC3) and angiopoietin-like protein 3 (ANGPTL3) inhibit lipolysis by lipoprotein lipase and may influence the secretion and uptake of various lipoproteins. Genetic studies show that depletion of these proteins is associated with improved lipid profiles and reduced cardiovascular events so it was anticipated that drugs which mimic the effects of loss-of-function mutations would be useful lipid treatments. ANGPTL3 inhibitors were initially developed as a treatment for severe hypertriglyceridaemia including familial chylomicronaemia syndrome (FCS), which is usually not adequately controlled with currently available drugs. However, it was found ANGPTL3 inhibitors were also effective in reducing low-density lipoprotein cholesterol (LDL-C) and they were studied in patients with homozygous familial hypercholesterolaemia (FH). Evinacumab targets ANGPTL3 and reduced LDL-C by about 50% in patients with homozygous FH and it has been approved for that indication. The antisense oligonucleotide (ASO) vupanorsen targeting ANGPTL3 was less effective in reducing LDL-C in patients with moderate hypertriglyceridaemia and its development has been discontinued but the small interfering RNA (siRNA) ARO-ANG3 is being investigated in Phase 2 studies. ApoC3 can be inhibited by the ASO volanesorsen, which reduced triglycerides by >70% in patients with FCS and it was approved for FCS in Europe but not in the United States because of concerns about thrombocytopaenia. Olezarsen is an N-acetylgalactosamine-conjugated ASO targeting apoC3 which appears as effective as volanesorsen without the risk of thrombocytopaenia and is undergoing Phase 3 trials. ARO-APOC3 is an siRNA targeting apoC3 that is currently being investigated in Phase 3 studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.